Correction: Posttranscriptional regulation of Galectin-3 by miR-128 contributes to colorectal cancer progression

Weiqun Lu; Jia Wang; Guohua Yang; Nanrong Yu; Zhiliang Huang; Houwei Xu; Jianchang Li; Jiliang Qiu; Xiang Zeng; Shicai Chen; Nan Li; Haiying Liu

doi:10.18632/oncotarget.24558

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Posttranscriptional regulation of Galectin-3 by miR-128 contributes to colorectal cancer progression

PDF | How to cite

Oncotarget. 2018; 9:12535-12535. https://doi.org/10.18632/oncotarget.24558

Metrics: PDF 1567 views | ?

Weiqun Lu^1,*, Jia Wang^1,*, Guohua Yang¹, Nanrong Yu¹, Zhiliang Huang¹, Houwei Xu¹, Jianchang Li¹, Jiliang Qiu¹, Xiang Zeng¹, Shicai Chen¹, Nan Li¹ and Haiying Liu¹

¹ Department of Gastrointestinal Neoplasms Surgery, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou 510095, Guangdong, China
^* These authors contributed equally to this work

Published: February 23, 2018

This article has been corrected: The updated Acknowledgments and Funding information is provided below:

ACKNOWLEDGMENTS AND FUNDING

This study was supported by grants from the National Natural Science Foundation of China (No. 81401989). Guangzhou Science and Technology Plan Projects (Health Medical Collaborative Innovation Program of Guangzhou) (No. 201400000001-4).

Original article: Oncotarget. 2017; 8:15242-15251. DOI: https://doi.org/10.18632/oncotarget.14839.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24558

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: Posttranscriptional regulation of Galectin-3 by miR-128 contributes to colorectal cancer progression